spacer
home > epc > spring 2018 > money matters
PUBLICATIONS
European Pharmaceutical Contractor

Money Matters

EPC: What are some of the challenges sites face when trying to be paid?

Dave Espenshade: A site’s ability to receive accurate and timely payments from sponsors or CROs is one of the most challenging processes it faces while conducting clinical trials. In fact, we often hear that payment terms are the biggest driver in a site’s ability to support a clinical study.

There are many reasons why this is such a challenge, with invoice adjudication being the biggest contributor to the limited transparency in the payment process. From a sponsor or CRO perspective, invoices are arriving in a variety of formats and often at different intervals. This causes a number of inconsistencies that their finance teams need to unravel to determine what work was performed, what rate was contracted, and what needs to be paid. This is a complex and difficult process, and, as a result, many sponsors and CROs pay their sites on a quarterly basis to keep up with this workload.

This time gap between services rendered and payment, along with the errors that often occur with payments, is one of the biggest challenges that sites face.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dave Espenshade is Vice President of CRO Partnerships at Greenphire. In his role, he leads the efforts to broaden the use of Greenphire’s solution suite among global CRO partners. Dave has more than two decades of experience in the software and life sciences industries and a demonstrated expertise in establishing successful partnerships between industryleading global CROs and software providers.
spacer
Dave Espenshade
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

SMI Immuno-Oncology Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of the field with a representation of the whole industry under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement